Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10549-010-1078-6.

Title:
Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers | Breast Cancer Research and Treatment
Description:
A majority of breast cancers are estrogen receptor (ER) positive and have a luminal epithelial phenotype. However, these ER+ tumors often contain heterogeneous subpopulations of ER− tumor cells. We previously identified a population of cytokeratin 5 (CK5) positive cells within ER+ and progesterone receptor positive (PR+) tumors that is both ER−PR− and CD44+, a marker of breast tumor-initiating cells (TICs). These CK5+ cells have properties of TICs in luminal tumor xenografts, and we speculated that they are more resistant to chemo- and anti-ER-targeted therapies than their ER+ neighbors. To test this, we used ER+PR+ T47D and MCF7 breast cancer cells. CK5+ cells had lower proliferative indices than CK5− cells, were less sensitive to 5-fluorouracil and docetaxel, and cultures became enriched for CK5+ cells after treatments. CK5+ cells were less prone to drug-induced apoptosis than CK5− cells. In cells treated with 17β-estradiol (E) plus anti-estrogens tamoxifen or fulvestrant, ER protein levels decreased, and CK5 protein levels increased, compared to controls treated with E alone. In ER+ tumors from patients treated with neoadjuvant endocrine therapies ER gene expression decreased, and CK5 gene expression increased in post compared to pre-treatment tumors. The number of CK5+ cells in tumors also increased in post- compared to pre-treatment tumors. We conclude that an ER−PR−CK5+ subpopulation found in many luminal tumors is resistant to standard endocrine and chemotherapies, relative to the majority ER+PR+CK5− cells. Compounds that effectively target these cells are needed to improve outcome in luminal breast cancers.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,603,724 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

breast, cancer, article, google, scholar, pubmed, cells, cas, receptor, cell, human, res, luminal, tumors, endocrine, stem, therapy, horwitz, estrogen, usa, research, cancers, expression, clin, oncol, cytokeratin, sartorius, tumor, access, resistance, privacy, cookies, content, positive, growth, molecular, natl, prognostic, university, colorado, medical, department, publish, search, steroid, negative, resistant, kabos, haughian, wang,

Topics {✒️}

month download article/chapter er−pr−ck5+ subpopulation found breast tumor-initiating cells majority er+pr+ck5− cells clinical oncology yia-pn200810-161 neoadjuvant endocrine therapy anti-er-targeted therapies tumorigenic breast-cancer cells node-positive breast cancer hormone receptor expression therapy resistant subpopulation tumor-initiating features er− tumor cells breast tumor xenografts full article pdf cd44+/cd24−/low cells anti-estrogens tamoxifen human breast carcinoma luminal breast cancers endocrine therapy residual breast cancers breast tumor heterogeneity breast cancer defined breast cancer subtypes recurrent breast cancer human breast tumours triple-negative phenotype luminal tumor xenografts cancer stem cells privacy choices/manage cookies neoplastic breast cells colorado cancer center primary breast cancers targeted therapies transforms primary breast cancer er+pr+ t47d steroid receptor negative triple-receptor measurements harvell dm progesterone receptor positive estrogen-receptor biology steroid receptor expression 5-bromo-2-deoxyuridine ck cheang mc creighton cj tumour stem cells luminal epithelial phenotype molecular profile subtype perou cm article kabos

Questions {❓}

  • O’Brien CS, Howell SJ, Farnie G et al (2009) Resistance to endocrine therapy: are breast cancer stem cells the culprits?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers
         description:A majority of breast cancers are estrogen receptor (ER) positive and have a luminal epithelial phenotype. However, these ER+ tumors often contain heterogeneous subpopulations of ER− tumor cells. We previously identified a population of cytokeratin 5 (CK5) positive cells within ER+ and progesterone receptor positive (PR+) tumors that is both ER−PR− and CD44+, a marker of breast tumor-initiating cells (TICs). These CK5+ cells have properties of TICs in luminal tumor xenografts, and we speculated that they are more resistant to chemo- and anti-ER-targeted therapies than their ER+ neighbors. To test this, we used ER+PR+ T47D and MCF7 breast cancer cells. CK5+ cells had lower proliferative indices than CK5− cells, were less sensitive to 5-fluorouracil and docetaxel, and cultures became enriched for CK5+ cells after treatments. CK5+ cells were less prone to drug-induced apoptosis than CK5− cells. In cells treated with 17β-estradiol (E) plus anti-estrogens tamoxifen or fulvestrant, ER protein levels decreased, and CK5 protein levels increased, compared to controls treated with E alone. In ER+ tumors from patients treated with neoadjuvant endocrine therapies ER gene expression decreased, and CK5 gene expression increased in post compared to pre-treatment tumors. The number of CK5+ cells in tumors also increased in post- compared to pre-treatment tumors. We conclude that an ER−PR−CK5+ subpopulation found in many luminal tumors is resistant to standard endocrine and chemotherapies, relative to the majority ER+PR+CK5− cells. Compounds that effectively target these cells are needed to improve outcome in luminal breast cancers.
         datePublished:2010-07-28T00:00:00Z
         dateModified:2010-07-28T00:00:00Z
         pageStart:45
         pageEnd:55
         sameAs:https://doi.org/10.1007/s10549-010-1078-6
         keywords:
            Tumor-initiating cells
            Estrogen receptors
            Endocrine therapy
            Tamoxifen
            Cytokeratin 5
            Breast cancer
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig6_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:128
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Peter Kabos
               affiliation:
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James M. Haughian
               affiliation:
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xinshuo Wang
               affiliation:
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wendy W. Dye
               affiliation:
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christina Finlayson
               affiliation:
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Department of Surgery, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anthony Elias
               affiliation:
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kathryn B. Horwitz
               affiliation:
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Carol A. Sartorius
               affiliation:
                     name:University of Colorado Anschutz Medical Campus
                     address:
                        name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers
      description:A majority of breast cancers are estrogen receptor (ER) positive and have a luminal epithelial phenotype. However, these ER+ tumors often contain heterogeneous subpopulations of ER− tumor cells. We previously identified a population of cytokeratin 5 (CK5) positive cells within ER+ and progesterone receptor positive (PR+) tumors that is both ER−PR− and CD44+, a marker of breast tumor-initiating cells (TICs). These CK5+ cells have properties of TICs in luminal tumor xenografts, and we speculated that they are more resistant to chemo- and anti-ER-targeted therapies than their ER+ neighbors. To test this, we used ER+PR+ T47D and MCF7 breast cancer cells. CK5+ cells had lower proliferative indices than CK5− cells, were less sensitive to 5-fluorouracil and docetaxel, and cultures became enriched for CK5+ cells after treatments. CK5+ cells were less prone to drug-induced apoptosis than CK5− cells. In cells treated with 17β-estradiol (E) plus anti-estrogens tamoxifen or fulvestrant, ER protein levels decreased, and CK5 protein levels increased, compared to controls treated with E alone. In ER+ tumors from patients treated with neoadjuvant endocrine therapies ER gene expression decreased, and CK5 gene expression increased in post compared to pre-treatment tumors. The number of CK5+ cells in tumors also increased in post- compared to pre-treatment tumors. We conclude that an ER−PR−CK5+ subpopulation found in many luminal tumors is resistant to standard endocrine and chemotherapies, relative to the majority ER+PR+CK5− cells. Compounds that effectively target these cells are needed to improve outcome in luminal breast cancers.
      datePublished:2010-07-28T00:00:00Z
      dateModified:2010-07-28T00:00:00Z
      pageStart:45
      pageEnd:55
      sameAs:https://doi.org/10.1007/s10549-010-1078-6
      keywords:
         Tumor-initiating cells
         Estrogen receptors
         Endocrine therapy
         Tamoxifen
         Cytokeratin 5
         Breast cancer
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-1078-6/MediaObjects/10549_2010_1078_Fig6_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:128
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Peter Kabos
            affiliation:
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James M. Haughian
            affiliation:
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xinshuo Wang
            affiliation:
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wendy W. Dye
            affiliation:
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christina Finlayson
            affiliation:
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Department of Surgery, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anthony Elias
            affiliation:
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kathryn B. Horwitz
            affiliation:
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Carol A. Sartorius
            affiliation:
                  name:University of Colorado Anschutz Medical Campus
                  address:
                     name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:128
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Department of Surgery, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
      name:University of Colorado Anschutz Medical Campus
      address:
         name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Peter Kabos
      affiliation:
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
      name:James M. Haughian
      affiliation:
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
      name:Xinshuo Wang
      affiliation:
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
      name:Wendy W. Dye
      affiliation:
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
      name:Christina Finlayson
      affiliation:
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Department of Surgery, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
      name:Anthony Elias
      affiliation:
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
      name:Kathryn B. Horwitz
      affiliation:
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
      name:Carol A. Sartorius
      affiliation:
            name:University of Colorado Anschutz Medical Campus
            address:
               name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
      name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
      name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
      name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
      name:Department of Surgery, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
      name:Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
      name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
      name:Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA
      name:Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(170)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.25s.